Silicon Valley’s Versant raises $134 mln to help fill Canada’s biotech VC gap
Versant Ventures has secured about $134 million (US$100 million) in commitments for a new fund earmarked to finance Canada’s biotech startups. In a news release, the Silicon Valley venture capital firm said Versant Voyageurs I will invest in five to eight companies in tandem with its primary life-sciences funds. Versant said the Canadian sidecar fund aims to address a shortage of risk capital and other resources available to local life-sciences companies. Managing Director Brad Bolzon, who will oversee the fund, said while Canada has “top-tier scientific infrastructure”, its VC and startup ecosystem has “not grown at the same pace.”
17 December 2018•2 mins read
